<DOC>
	<DOC>NCT00635973</DOC>
	<brief_summary>A trial to assess patients who have been treated with Iressa in a previous clinical trial and may benefit from continued treatment with Iressa.</brief_summary>
	<brief_title>Open-Label Extension of Other SZ1839 (Iressa) Trials</brief_title>
	<detailed_description />
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Received treatment in a previous Iressa clinical trial Provided Informed Consent to participate in the trial 30 days or less since completing the previous Iressa trial. Radiotherapy completed more than 14 days before starting treatment in this trial Incomplete healing from prior surgery Withdrawal from previous Iressa trial due to unacceptable toxicity to major organs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Iressa</keyword>
	<keyword>Gefitinib</keyword>
	<keyword>Cancer</keyword>
	<keyword>Patients diagnosed with cancer who have previously received Iressa in an Iressa clinical trial</keyword>
</DOC>